348 related articles for article (PubMed ID: 29235195)
1. Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.
Zhu H; Lai YS; Li Y; Blum RH; Kaufman DS
Stem Cells; 2018 Feb; 36(2):134-145. PubMed ID: 29235195
[TBL] [Abstract][Full Text] [Related]
2. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
Zhu H; Kaufman DS
Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
[TBL] [Abstract][Full Text] [Related]
3. Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions.
Matsubara H; Niwa A; Nakahata T; Saito MK
Biochem Biophys Res Commun; 2019 Jul; 515(1):1-8. PubMed ID: 30948156
[TBL] [Abstract][Full Text] [Related]
4. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
Zhu H; Kaufman DS
Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
[TBL] [Abstract][Full Text] [Related]
5. Pluripotent stem cell-derived natural killer cells for cancer therapy.
Knorr DA; Kaufman DS
Transl Res; 2010 Sep; 156(3):147-54. PubMed ID: 20801411
[TBL] [Abstract][Full Text] [Related]
6. Development of innate immune cells from human pluripotent stem cells.
Bernareggi D; Pouyanfard S; Kaufman DS
Exp Hematol; 2019 Mar; 71():13-23. PubMed ID: 30611869
[TBL] [Abstract][Full Text] [Related]
7. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
Knorr DA; Ni Z; Hermanson D; Hexum MK; Bendzick L; Cooper LJ; Lee DA; Kaufman DS
Stem Cells Transl Med; 2013 Apr; 2(4):274-83. PubMed ID: 23515118
[TBL] [Abstract][Full Text] [Related]
8. Advantages and clinical applications of natural killer cells in cancer immunotherapy.
Ames E; Murphy WJ
Cancer Immunol Immunother; 2014 Jan; 63(1):21-8. PubMed ID: 23989217
[TBL] [Abstract][Full Text] [Related]
9. iPSC-Derived Natural Killer Cells for Cancer Immunotherapy.
Karagiannis P; Kim SI
Mol Cells; 2021 Aug; 44(8):541-548. PubMed ID: 34373366
[TBL] [Abstract][Full Text] [Related]
10. Directed differentiation of induced pluripotent stem cells towards T lymphocytes.
Lei F; Haque R; Xiong X; Song J
J Vis Exp; 2012 May; (63):e3986. PubMed ID: 22617911
[TBL] [Abstract][Full Text] [Related]
11. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
Hermanson DL; Bendzick L; Pribyl L; McCullar V; Vogel RI; Miller JS; Geller MA; Kaufman DS
Stem Cells; 2016 Jan; 34(1):93-101. PubMed ID: 26503833
[TBL] [Abstract][Full Text] [Related]
12. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
13. Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective.
Jin G; Chang Y; Harris JD; Bao X
Cells Tissues Organs; 2023; 212(5):439-467. PubMed ID: 36599319
[TBL] [Abstract][Full Text] [Related]
14. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
15. [Basic Research and Clinical Development of Regenerative Immunotherapy Using iPS Cells].
Kanie K; Kaneko S
Gan To Kagaku Ryoho; 2023 May; 50(5):571-576. PubMed ID: 37218314
[TBL] [Abstract][Full Text] [Related]
16. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
Nianias A; Themeli M
Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
[TBL] [Abstract][Full Text] [Related]
17. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
18. Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.
Haque M; Song J; Fino K; Sandhu P; Wang Y; Ni B; Fang D; Song J
Cell Transplant; 2016; 25(5):811-27. PubMed ID: 26777320
[TBL] [Abstract][Full Text] [Related]
19. When CAR Meets Stem Cells.
Lee JM
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013813
[TBL] [Abstract][Full Text] [Related]
20. 'Off the shelf' immunotherapies: Generation and application of pluripotent stem cell-derived immune cells.
Wang C; Liu J; Li W
Cell Prolif; 2023 Apr; 56(4):e13425. PubMed ID: 36855955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
